



Professor XU Hong-xi

Professor Xu Hong-xi has studied and worked abroad for more than 20 years. He has been actively involved in Chinese Medicine research in various institutions in Japan, Singapore, Canada and Hong Kong. He has been appointed as a Full-time Professor of Shanghai University of Traditional Chinese Medicine since 2011 and is currently the Dean of the School of Pharmacy. In recognition of his distinguished achievements, Professor Xu was selected in the sixth batch of the Thousand Talents Program (The Recruitment Program of Global Experts), and serve as a “Specially-Appointed Professor of Shanghai”. Prof. Xu has published more than 200 SCI papers, and obtained one PCT patent and eight US patents. He has delivered invited and keynote speeches in various countries and regions, including the United States, Japan, Singapore, Korea, Austria, Canada, India, Brazil, Russia, Taiwan, Hong Kong and Macao.

Prof. Xu obtained his Ph.D degree in Pharmaceutical Sciences in 1994 from Toyama Medical and Pharmaceutical University in Japan. He has previously served as the Scientific Officer and R & D Manager in the Institute of Chinese Medicine at the Chinese University of Hong Kong, the Deputy General Manager and Senior Medical Advisor of Hutchison Whampoa (China) Ltd, the Board of Director and R & D Director at Shanghai Hutchison Pharmaceuticals. From 2001 to 2010, he served as the Deputy Director of Hong Kong Jockey Club Institute of Chinese Medicine. His major social appointments include: the Chairman of Chinese Medicine Experimental Pharmacology Branch of China Association of Chinese Medicine, the Chairman of Chinese Medicine Branch of Shanghai Pharmaceutical Association, the Vice-President of The Foundation Conference of TCM Pharmaceutical Analysis Specialty Committee of the World Federation of Chinese Medicine, Chinese Medicine Patent Evaluation Expert of Chinese Medicine Council of Hong Kong, and the Co-Chairman of International Conference of the Modernization of Chinese Medicine (ICMCM). He is also the Associate Editor of *Chinese Medicine* and the Editorial Board Member of more than 10 scientific journals.

His current research interest is focused on new drug discovery from natural resources, as well as the development of botanical dietary supplements from herbal medicines. Specifically, he is interested in finding natural lead compounds from medicinal plants and in developing new drug based on Chinese medicines against different disease targets such as cancer, HIV, HSV, HBV and metabolic diseases. He applies multiple assay models targeting cell death (e.g. apoptosis, autophagy), metastasis, and quiescent cell recurrence to screen for anti-cancer natural compounds. With state-of-the-art technologies, he investigates the in vitro and in vivo mechanisms of action of the novel compounds from medicinal plants.